Search results

Skip to results

Area of interest

Area of interest

Type

Type

Status

Status

Last updated

Last updated

Guidance programme

Advice programme

Showing 16 to 30 of 85 results for cell transplantation

  1. Bosutinib for previously treated chronic myeloid leukaemia (TA401)

    Evidence-based recommendations on bosutinib (Bosulif) for previously reated chronic myeloid leukaemia in adults.

    Technology appraisal guidance
    Published
    24 August 2016
    View recommendations

    Sections for TA401

  2. Holoclar for treating limbal stem cell deficiency after eye burns (TA467)

    Evidence-based recommendations on Holoclar (a layer of cells grown from cells taken from your own eye) for treating limbal stem cell deficiency in adults with eye burns.

    Technology appraisal guidance
    Published
    16 August 2017
    View recommendations

    Sections for TA467

  3. Dasatinib, nilotinib and imatinib for untreated chronic myeloid leukaemia (TA426)

    Evidence-based recommendations on dasatinib (Sprycel), nilotinib (Tasigna) and imatinib (Glivec) for untreated chronic myeloid leukaemia in adults.

    Technology appraisal guidance
    Published
    21 December 2016
    View recommendations

    Sections for TA426

  4. Blinatumomab for treating acute lymphoblastic leukaemia in remission with minimal residual disease activity (TA589)

    Evidence-based recommendations on blinatumomab (Blincyto) for treating Philadelphia-chromosome-negative CD19-positive B-precursor acute lymphoblastic leukaemia in remission with minimal residual disease activity in adults.

    Technology appraisal guidance
    Published
    24 July 2019
    View recommendations

    Sections for TA589

  5. Brentuximab vedotin for treating CD30-positive Hodgkin lymphoma (TA524)

    Evidence-based recommendations on brentuximab vedotin (Adcetris) for treating CD30-positive Hodgkin lymphoma in adults.

    Technology appraisal guidance
    Published
    13 June 2018
    View recommendations

    Sections for TA524

  6. Atidarsagene autotemcel for treating metachromatic leukodystrophy (HST18)

    Evidence-based recommendations on atidarsagene autotemcel (Libmeldy) for treating metachromatic leukodystrophy in children.

    Highly specialised technologies guidance
    Published
    28 March 2022
    View recommendations

    Sections for HST18

  7. Azacitidine for the treatment of myelodysplastic syndromes, chronic myelomonocytic leukaemia and acute myeloid leukaemia (TA218)

    Evidence-based recommendations on azacitidine (Vidaza) for treating myelodysplastic syndromes, chronic myelomonocytic leukaemia and acute myeloid leukaemia in adults.

    Technology appraisal guidance
    Published
    23 March 2011
    View recommendations

    Sections for TA218

  8. Pancreatic islet cell transplantation (IPG13)

    NICE's guidance on pancreatic islet cell transplantation has now been replaced. Please go to NICE interventional procedure guidance 257 to view the full guidance on allogeneic pancreatic islet cell transplantation for type 1 diabetes mellitus and to NICE interventional procedure guidance 274 to view the full guidance on autologous pancreatic islet cell transplantation for improved glycaemic control after pancreatectomy issued to the NHS in England, Wales, Scotland and Northern Ireland.

    Interventional procedures guidance
    Published
    17 February 2003

  9. Brentuximab vedotin for treating relapsed or refractory systemic anaplastic large cell lymphoma (TA478)

    Evidence-based recommendations on brentuximab vedotin (Adcetris) for treating relapsed or refractory systemic anaplastic large cell lymphoma in adults.

    Technology appraisal guidance
    Published
    4 October 2017
    View recommendations

    Sections for TA478

  10. Past appeals and decisions

    TA482 Kidney transplantation (adults) - immunosuppressive therapy (review) 30 March 2016 TA482 Kidney transplantation...

  11. Autologous haematopoietic stem cell transplantation for treating multiple sclerosis [ID1111]

    Discontinued [GID-TA10306]

    Technology appraisal guidance
    Discontinued

  12. Axicabtagene ciloleucel for treating diffuse large B-cell lymphoma and primary mediastinal large B-cell lymphoma after 2 or more systemic therapies (TA872)

    Evidence-based recommendations on axicabtagene ciloleucel (Yescarta) for treating diffuse large B-cell lymphoma and primary mediastinal large B-cell lymphoma in adults after 2 or more systemic therapies.

    Technology appraisal guidance
    Published
    28 February 2023

    Sections for TA872

  13. Ponatinib for treating chronic myeloid leukaemia and acute lymphoblastic leukaemia (TA451)

    Evidence-based recommendations on ponatinib (Iclusig) for treating chronic myeloid leukaemia and acute lymphoblastic leukaemia in adults.

    Technology appraisal guidance
    Published
    28 June 2017
    View recommendations

    Sections for TA451

  14. Reducing the risk of complications of anticancer treatment in children and young people, and in adults diagnosed with lymphoma:- Randomised studies should investigate primary prophylaxis of neutropenic sepsis in 2 populations: children and young people (aged under 18) having treatment for solid tumours or haematological malignancies, or stem cell transplantation; and adults (aged 18 and older) diagnosed with lymphoma. The studies should compare the effectiveness of fluoroquinolone antibiotics given alone, fluoroquinolone antibiotics given together with G-CSF preparations, and G-CSF preparations given alone. Outcome measures should include overall mortality, infectious episodes and adverse events. In addition, quality of life should be determined using quantitative and qualitative methods. The resulting data should be used to develop a cost-effectiveness analysis comparing these 3 forms of prophylaxis in children and young people having anticancer treatment, and in adults diagnosed with lymphoma.

    treatment for solid tumours or haematological malignancies, or stem cell transplantation; and adults (aged 18 and older) diagnosed with...

    Research recommendation
    Published
    9 June 2015

  15. Acalabrutinib with bendamustine and rituximab for untreated mantle cell lymphoma [ID6155]

    In development [GID-TA11091] Expected publication date: 20 August 2025

    Technology appraisal guidance
    In development